Wish Recovery’s Blog Monthly Archives

You started the medication for your weight. Then something else happened. The urge to drink—or the pull toward whatever it was—got quieter. You didn't expect that. And now you're here, at whatever hour this is, trying to figure out if what you're noticing is real, and what, if anything, it means.

It's real. The research says so. And the question worth sitting with is this: if the room is quieter now, what do you want to do with the space?

Key Takeaways

• GLP-1 medications like semaglutide are showing meaningful reductions in alcohol and opioid cravings in clinical research.
• The same brain pathways that drive overeating also drive substance cravings—GLP-1 medications act on both.
• Medication alone rarely sustains recovery; structured outpatient support addresses what lives underneath the cravings.
• Luxury IOP allows you to continue your daily life, including GLP-1 treatment, while receiving intensive, personalized care.
• GLP-1 medications are not FDA-approved for addiction treatment; clinical integration requires individualized, physician-guided planning.

Ready to find your level of care? Talk to a clinician at Wish Recovery IOP.